Mark A. Velleca's most recent trade in Black Diamond Therapeutics Inc was a trade of 500,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 75,000 | 121,522 (0%) | 0% | 0 | Common Stock | |
| Black Diamond Therapeutics Inc | Velleca Mark A. | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 537,000 | 537,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 08 Aug 2023 | 57,286 | 173,286 (0%) | 0% | 0.4 | 22,342 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 08 Aug 2023 | 57,286 | 116,000 (0%) | 0% | 2.0 | 114,492 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 57,286 | 0 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 2,714 | 242,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 08 Aug 2023 | 2,714 | 118,714 (0%) | 0% | 0.3 | 814 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 2.02 per share. | 08 Aug 2023 | 2,714 | 116,000 (0%) | 0% | 2.0 | 5,482 | Common Stock |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 2.10 per share. | 16 Jun 2023 | 8,929 | 41,314 (0%) | 0% | 2.1 | 18,751 | Common Stock |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 1.67 per share. | 16 Mar 2023 | 11,228 | 32,385 (0%) | 0% | 1.7 | 18,751 | Common Stock |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 16 Dec 2022 | 8,424 | 21,157 (0%) | 0% | 1.5 | 12,636 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2022 | 15,000 | 57,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 11.70 per share. | 18 Oct 2022 | 15,000 | 116,000 (0%) | 0% | 11.7 | 175,490 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 18 Oct 2022 | 15,000 | 131,000 (0%) | 0% | 0.4 | 5,850 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 20 Sep 2022 | 20,000 | 136,000 (0%) | 0% | 0.4 | 7,800 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2022 | 20,000 | 72,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 13.50 per share. | 20 Sep 2022 | 20,000 | 116,000 (0%) | 0% | 13.5 | 270,044 | Common Stock |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 2.62 per share. | 16 Sep 2022 | 4,294 | 12,733 (0%) | 0% | 2.6 | 11,250 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 12.64 per share. | 16 Aug 2022 | 80,000 | 116,000 (0%) | 0% | 12.6 | 1,010,904 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 80,000 | 92,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 16 Aug 2022 | 80,000 | 196,000 (0%) | 0% | 0.4 | 31,200 | Common Stock |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 2.03 per share. | 17 Jun 2022 | 5,542 | 8,439 (0%) | 0% | 2.0 | 11,250 | Common Stock |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 3.02 per share. | 18 Mar 2022 | 2,897 | 2,897 (0%) | 0% | 3.0 | 8,749 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 15,000 | 172,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 07 Feb 2022 | 15,000 | 116,000 (0%) | 0% | 0.4 | 5,850 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 09 Nov 2021 | 40,000 | 101,000 (0%) | 0% | 0.4 | 15,600 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 40,000 | 187,286 | - | - | Stock Options (Right to Buy) | |
| Black Diamond Therapeutics Inc | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 237,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 247,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 18.49 per share. | 13 Jul 2021 | 10,000 | 61,000 (0%) | 0% | 18.5 | 184,898 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Jul 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 13 Jul 2021 | 10,000 | 61,000 (0%) | 0% | 19.1 | 190,824 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Jul 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 13 Jul 2021 | 10,000 | 61,000 (0%) | 0% | 19.5 | 194,536 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Jul 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 227,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 15 Jun 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 257,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 267,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 277,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 21.77 per share. | 15 Jun 2021 | 10,000 | 61,000 (0%) | 0% | 21.8 | 217,728 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 15 Jun 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 21.74 per share. | 15 Jun 2021 | 10,000 | 61,000 (0%) | 0% | 21.7 | 217,384 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 15 Jun 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 22.39 per share. | 15 Jun 2021 | 10,000 | 61,000 (0%) | 0% | 22.4 | 223,909 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 20,000 | 287,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 25 May 2021 | 20,000 | 61,000 (0%) | 0% | 0.4 | 7,800 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 11 May 2021 | 10,000 | 41,000 (0%) | 0% | 19.1 | 190,997 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 307,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 317,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 327,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.54 per share. | 11 May 2021 | 10,000 | 41,000 (0%) | 0% | 20.5 | 205,413 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 May 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 11 May 2021 | 10,000 | 41,000 (0%) | 0% | 20.1 | 200,691 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 May 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 May 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 357,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Apr 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 23.89 per share. | 13 Apr 2021 | 10,000 | 41,000 (0%) | 0% | 23.9 | 238,865 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Apr 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 24.53 per share. | 13 Apr 2021 | 10,000 | 41,000 (0%) | 0% | 24.5 | 245,272 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Apr 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 24.96 per share. | 13 Apr 2021 | 10,000 | 41,000 (0%) | 0% | 25.0 | 249,631 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 347,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 337,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Feb 2021 | 11,040 | 52,040 (0%) | 0% | 3.7 | 41,069 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 11,040 | 48,393 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 10,000 | 28,393 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 10,000 | 38,393 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 26.02 per share. | 16 Feb 2021 | 10,000 | 41,000 (0%) | 0% | 26.0 | 260,152 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Feb 2021 | 10,000 | 51,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Feb 2021 | 10,000 | 51,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 27.59 per share. | 16 Feb 2021 | 9,400 | 41,600 (0%) | 0% | 27.6 | 259,387 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 34.87 per share. | 16 Feb 2021 | 8,317 | 43,723 (0%) | 0% | 34.9 | 290,021 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 36.22 per share. | 16 Feb 2021 | 2,700 | 41,023 (0%) | 0% | 36.2 | 97,781 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 28.41 per share. | 16 Feb 2021 | 600 | 41,000 (0%) | 0% | 28.4 | 17,046 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 37.00 per share. | 16 Feb 2021 | 23 | 41,000 (0%) | 0% | 37 | 851 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 19 Jan 2021 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 10,000 | 59,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 10,000 | 69,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 10,000 | 79,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.64 per share. | 19 Jan 2021 | 10,000 | 41,000 (0%) | 0% | 20.6 | 206,400 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 19 Jan 2021 | 10,000 | 51,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 19 Jan 2021 | 10,000 | 37,000 (0%) | 0% | 21.5 | 215,107 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 19 Jan 2021 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.88 per share. | 19 Jan 2021 | 10,000 | 37,000 (0%) | 0% | 20.9 | 208,781 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 4,000 | 367,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 19 Jan 2021 | 4,000 | 41,000 (0%) | 0% | 0.4 | 1,560 | Common Stock |